Chris co-founded Vision Medicines in May 2013. In September 2010, Chris co-founded Blueprint Medicines, a leading oncology therapeutics company located in Cambridge, MA. Chris served as Blueprint’s President, CE0, and Director from its founding in May 2013. He built the company by developing the corporate and scientific strategy, recruiting a world class team, and raising $40M in a Series-A financing from Third Rock Ventures and Fidelity Bio. Blueprint Medicines went public in April 2015 (Nasdaq: BPMC). Previously at Third Rock Ventures as an entrepreneur-in-residence, Chris also co-founded and led Warp Drive Bio, which executed a $125M strategic partnership with Sanofi.
Prior to Third Rock Ventures, Chris was a partner at Flagship Ventures focusing on life science investments such as Tetraphase Pharmaceuticals, which went public in March 2013 (Nasdaq: TTPH). During his last year at Flagship, he also served as the president, chief executive officer and director of Selventa, Inc. (f.k.a. Genstruct, Inc.), a Flagship portfolio company. Before joining Flagship, he oversaw efforts spanning clinical development, business development and sales and marketing at Novartis AG. Prior to Novartis, he was at the U.S. Food and Drug Administration in the Office of Combination Products and at Millennium Pharmaceuticals in the Personalized Medicines group. Chris holds a PhD in biomedical sciences from Harvard Medical School and the Massachusetts Institute of Technology through the joint division of Health Sciences and Technology (HST), a MS in Management of Science and Engineering from Stanford University, a MS in Computer Science from Stanford University, and a BS in Computer Science from Stanford University.